Poolbeg Pharma PLC
Total Valuation
GBXAs of December 31, 2025, Poolbeg Pharma PLC carries a market capitalization of 2.79B, placing it among publicly traded companies globally. Its enterprise value stands at 2.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.79B |
| Enterprise Value | 2.02B |
Important Dates
Poolbeg Pharma PLC's next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
Share Statistics
As of December 31, 2025, Poolbeg Pharma PLC has 697.20M shares outstanding.
| Shares Outstanding | 697.20M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | 3.24 |
| P/TBV Ratio | 4.03 |
Financial Position
As of December 31, 2025, Poolbeg Pharma PLC maintains a current ratio of 6.17, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.17 |
| Quick Ratio | 5.75 |
Stock Price Statistics
GBXAs of the close on October 22, 2026, Poolbeg Pharma PLC's stock has gained approximately 85.71% over the past 52 weeks. The 50-day moving average sits at 7.89, while the 200-day moving average is 6.05.
| 52-Week Price Change | 85.71% |
| 50-Day Moving Average | 7.89 |
| 200-Day Moving Average | 6.05 |
Balance Sheet
GBXThese figures are as of December 31, 2025. Total book value stands at 860.10M, with working capital of 692.70M providing operational flexibility.
| Cash & Cash Equivalents | 771.30M |
| Net Debt | -771.30M |
| Equity (Book Value) | 860.10M |
| Book Value Per Share | 1.23 |
| Working Capital | 692.70M |